Ugo Testa


Affiliation: Istituto Superiore di Sanit
Country: Italy


  1. Testa U, Petrucci E, Pasquini L, Castelli G, Pelosi E. Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines (Basel). 2018;5: pubmed publisher
    ..The improvements in our understanding of the molecular and cellular basis of ovarian cancers should lead to more efficacious treatments. ..
  2. Testa U, Castelli G, Elvira P. Experimental and investigational therapies for chemotherapy-induced anemia. Expert Opin Investig Drugs. 2015;24:1433-45 pubmed publisher
    ..It is also important to carefully evaluate CIA patients to properly assess the physiopathological mechanisms responsible for the development of their anemic condition and provide patients with the most appropriate treatment plan. ..
  3. Castelli G, Pelosi E, Testa U. Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers (Basel). 2019;11: pubmed publisher
    ..Overall, these observations strongly support the view that the targeting of mitochondrial apoptotic or metabolic machinery is an appealing new therapeutic perspective in AML. ..
  4. Testa U, Castelli G, Pelosi E. Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Med Sci (Basel). 2018;6: pubmed publisher
  5. Testa U, Pannitteri G, Condorelli G. Vascular endothelial growth factors in cardiovascular medicine. J Cardiovasc Med (Hagerstown). 2008;9:1190-221 pubmed publisher
    ..Challenges still remain about the type or the combination of angiogenic factors to be administered, the form (protein vs. gene), the route, and the duration of administration. ..
  6. Testa U. Erythropoietic stimulating agents. Expert Opin Emerg Drugs. 2010;15:119-38 pubmed publisher
    ..New ESAs are under development and their introduction in therapy could provide a significant improvement in anemia management. ..
  7. Riccioni R, Lulli V, Castelli G, Biffoni M, Tiberio R, Pelosi E, et al. miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias. Leuk Res. 2015;39:221-8 pubmed publisher
    ..Together, these findings suggest that deregulated miR-21 expression may contribute to disease pathogenesis in NPM1-mutated AMLs. ..
  8. request reprint
    Testa U. Proteasome inhibitors in cancer therapy. Curr Drug Targets. 2009;10:968-81 pubmed
    ..The ensemble of these drugs offers the scenario of the possible development of a family of proteasome inhibitors, contributing a drug arsenal for the therapy of cancer and other diseases. ..
  9. Testa U. Leukemia stem cells. Ann Hematol. 2011;90:245-71 pubmed publisher

More Information


  1. Testa U, Castelli G, Pelosi E. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel). 2018;10: pubmed publisher
    ..Molecular studies performed on lung tumors during treatment have shown the phenomenon of clonal evolution, thus supporting the occurrence of a temporal tumor heterogeneity. ..
  2. Testa U, Pelosi E, Castelli G, Labbaye C. miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development. Noncoding RNA. 2017;3: pubmed publisher
    ..The demonstration that miR-155 overexpression plays a key pathogenic role in some lymphomas and acute myeloid leukemias has led to the development of an antagomir-based approach as a new promising therapeutic strategy. ..
  3. Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel). 2018;6: pubmed publisher
    ..Colon cancer stem cells seem to be involved in tumor chemoresistance, radioresistance and relapse. ..
  4. Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol. 2009;88:505-28 pubmed publisher
    ..The increase in HbF in response to these drugs varies among patients with beta-thalassemia and sickle cell disease due to individual genetic determinants. ..
  5. Saulle E, Petronelli A, Pelosi E, Coppotelli E, Pasquini L, Ilari R, et al. PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response. J Hematol Oncol. 2016;9:33 pubmed publisher
    ..Our data suggest that HHEX downmodulation by PML-RAR? is a key event during APL pathogenesis. ..
  6. Testa U, Lo Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016;95:673-80 pubmed publisher
  7. Castelli G, Parolini I, Cerio A, D Angiò A, Pasquini L, Carollo M, et al. Conditioned medium from human umbilical vein endothelial cells markedly improves the proliferation and differentiation of circulating endothelial progenitors. Blood Cells Mol Dis. 2016;61:58-65 pubmed publisher
    ..These observations provided the interesting indication that mature ECs exert a stimulatory effect on endothelial cell differentiation from CD34(+) cells. ..
  8. Pelosi E, Castelli G, Testa U. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines. 2017;5: pubmed publisher
    ..The study of these cells could contribute to the identification and clinical development of more efficacious drug treatments. ..
  9. Testa U, Castelli G, Pelosi E. Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Med Sci (Basel). 2017;5: pubmed publisher
  10. Mastrangelo D, Pelosi E, Castelli G, Lo Coco F, Testa U. Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation. Blood Cells Mol Dis. 2018;69:57-64 pubmed publisher
    ..Pre-clinical studies have led to identify tumors sensitive to Ascorbate that could potentially benefit from this treatment either through an epigenetic modulator effect or through tumor killing by oxidative stress. ..
  11. Testa U, Castelli G, Pelosi E. Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. Medicines (Basel). 2017;4: pubmed publisher
    ..The reviewed studies suggest that current molecular and cellular characterization of EAC and ESCC should serve as background for development of new treatment strategies. ..
  12. Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel). 2017;9: pubmed publisher
    ..The identification and definition of liver cancer stem cells requires both immunophenotypic and functional properties. ..